June 20, 2026
TTime vs Hims: Enclomiphene Cost and Program Compared
TTime vs Hims for enclomiphene? Both are U.S. telehealth programs, but the headline price gap (about $69 vs $99/mo) is only the start. Here is how to compare them on real 90-day cost, labs, and onboarding - not just the sticker.
TTime vs Hims is one of the most common enclomiphene matchups, and it usually comes down to one number: TTime anchors lower (about $69/mo) while Hims commonly starts near $99/mo on longer plans. A roughly $30 monthly gap is real, but it is not the whole story. Here is how to compare the two like an adult instead of picking the smaller sticker.
The headline difference
TTime positions itself at one of the lower published anchors in the category with a streamlined start. Hims is a large, established platform with a structured onboarding flow and multi-month plans where longer commitments lower the effective monthly rate. On price alone, TTime usually wins the headline; on brand scale and ecosystem, Hims is the bigger operation.
Why the sticker price can mislead
- Labs: whether bloodwork is bundled or billed separately can erase a $30/mo gap over a quarter.
- Plan length: both brands discount longer commitments, so compare the same duration.
- Shipping and add-ons: confirm what is included before comparing monthly anchors.
- Ongoing vs intro pricing: an attractive first month can revert to a higher renewal rate.
The honest way to decide is a 90-day all-in total for each: medication + labs + shipping. Our TTime pricing breakdown walks through that math, and the side-by-side TTime vs Hims comparison grid lays out the fields next to each other.
Where each one tends to fit
If lowest published entry price and a fast start matter most, TTime is built around that. If you value a large, broad telehealth ecosystem with other services under one login, Hims has scale. Neither replaces the only decision that matters clinically: whether enclomiphene is right for your labs, judged by a prescriber.
Prefer a wider field than just these two? See TTime alternatives compared and the TTime provider page for live details.
FAQ
Is TTime cheaper than Hims?
On headline price, usually yes - TTime anchors near $69/mo versus about $99/mo for Hims. But whether it is cheaper for you depends on labs, plan length, and shipping, so compare a full 90-day total rather than the monthly sticker.
Is TTime or Hims better for enclomiphene?
Neither is universally 'better.' TTime emphasizes a low entry price and fast start; Hims offers a larger telehealth ecosystem. The right choice depends on your budget, the bundle, and - most importantly - clinician judgment on whether enclomiphene fits your labs.
Do TTime and Hims both require labs?
Reputable enclomiphene programs use bloodwork to confirm appropriateness and measure results. Confirm on each official site whether labs are required before or after the first order and whether they are bundled or billed separately.
Authoritative references (education)
Independent references for core definitions and labeling-not a substitute for your clinician’s judgment about your case.
You might also like
More articles on T-Compare, plus quick links to our comparison tools.
- Critical T and Workouts: Can It Help Your Training and Recovery?
Can Critical T actually help in the gym? Testosterone matters for strength, muscle, and recovery - so here is a realistic look at how a Tongkat Ali-based supplement fits training, what to expect, and what it won't do.
Read article → - Signs of Low Testosterone in Men: What to Watch For
Fatigue, low drive, brain fog, lost strength - the signs of low testosterone are easy to dismiss as 'just aging.' Here is a clear rundown of the common symptoms, when to get labs, and where supplements like Critical T fit.
Read article → - Critical T vs TestoFuel: Estrogen Balance vs Muscle-Building Booster
Critical T vs TestoFuel - one is an estrogen-balance testosterone stack, the other a muscle-building-focused booster favored by bodybuilders. Here is how they compare on formula, price, guarantee, and who each one suits.
Read article →